Immatics N.V. (IMTXW)
- Previous Close
2.2500 - Open
2.2200 - Bid --
- Ask --
- Day's Range
2.0100 - 2.2200 - 52 Week Range
2.0100 - 2.2200 - Volume
4,200 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
www.immatics.comRecent News: IMTXW
Compare To: IMTXW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMTXW
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-179.63%
Return on Assets (ttm)
-13.85%
Return on Equity (ttm)
-44.26%
Revenue (ttm)
54M
Net Income Avi to Common (ttm)
-96.99M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
425.9M
Total Debt/Equity (mrq)
6.84%
Levered Free Cash Flow (ttm)
-25.99M
Company Insights: IMTXW
IMTXW does not have Company Insights